Summary: Stem cell study reveals a genetic defect associated with fragile X syndrome delays the production of neurons during a critical stage of embryonic development.
Source: Ann & Robert H. Lurie Children’s Hospital of Chicago
The lab of Yongchao Ma, PhD, from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, discovered how the genetic defect in fragile X syndrome – a type of autism – delays production of neurons (nerve cells) at a critical time in the embryo’s brain development. In a study published in Cell Reports, Dr. Ma and colleagues describe a previously unknown regulatory mechanism controlling how stem cells differentiate into neurons. They identified early disruptions in this process in fragile X syndrome, the most common inherited intellectual disability in children.
“During embryonic brain development, the right neurons have to be produced at the right time and in the right numbers,” says Dr. Ma, senior author, and researcher at Lurie Children’s, as well as Associate Professor of Pediatrics, Neurology, and Physiology at Northwestern University Feinberg School of Medicine. “We focused on what happens in the stem cells that lead to slower production of neurons that are responsible for brain functions including learning and memory. Our discoveries shed light on the earliest stages of disease development and offer novel targets for potential treatments.”
Other studies in fragile X development have focused on the interactions between mature neurons. Dr. Ma’s study is the first to offer a new understanding of the disease at a stem cell level.
Fragile X syndrome occurs in approximately 1 in 4,000 males and 1 in 8,000 females. It is caused by a mutation in the gene called FMR1 that encodes a protein called FMRP. The genetic defect leads to reduced FMRP protein. Previously the function of FMRP protein during early brain development was not known.
Dr. Ma and colleagues discovered that within a stem cell, the FMRP protein plays a key role as a “reader” of a chemical tag (called m6A) on the RNA. This tag carries instructions on how to process the RNA. By reading these instructions, FMRP protein exports the RNAs from the nucleus to the cytoplasm of cells where the m6A-tagged RNAs will become proteins that control stem cell differentiation into neurons.
“We show how the reduced amount of FMRP protein in neural stem cell results in decreased nuclear export of m6A-tagged RNAs and ultimately, slower production of the neurons that are essential for healthy brain development,” says first author Brittany Edens, graduate student in the Northwestern University Interdepartmental Neuroscience Program who works in Dr. Ma’s lab. “Our findings also expand understanding of how the flow of genetic information from DNA to RNA to protein is regulated, which is a central question in biology.”
“Currently we are exploring how to stimulate FMRP protein activity in the stem cell, in order to correct the timing of neuron production and ensure that the correct amount and types of neurons are available to the developing brain,” says Dr. Ma. “There may be potential for gene therapy for fragile X syndrome.”
Funding: This research was supported by grants from the National Institutes of Health, the Simons Foundation Autism Research Initiative, Cure SMA, The Hartwell Foundation and the Chicago Biomedical Consortium.
Ann & Robert H. Lurie Children’s Hospital of Chicago
Vita Lerman – Ann & Robert H. Lurie Children’s Hospital of Chicago
The image is in the public domain.
Original Research: Open access
“FMRP Modulates Neural Differentiation through m6A-Dependent mRNA Nuclear Export”. Brittany M. Edens,Caroline Vissers,Jing Su,Saravanan Arumugam,Zhaofa Xu,Han Shi,Nimrod Miller,Francisca Rojas Ringeling,Guo-li Ming,Chuan He,Hongjun Song,Yongchao C. Ma.
Cell Reports. doi:10.1016/j.celrep.2019.06.072
FMRP Modulates Neural Differentiation through m6A-Dependent mRNA Nuclear Export
• FMRP reads m6A to promote mRNA nuclear export in neural differentiation
• Neural progenitor differentiation is delayed by knockout (KO) of Fmr1 or Mettl14
• Both Mettl14KO and Fmr1KO lead to nuclear retention of m6A-tagged FMRP target mRNAs
• FMRP preferentially binds m6A-tagged mRNAs to facilitate nuclear export through CRM1
N6-methyladenosine (m6A) modification of mRNA is emerging as a vital mechanism regulating RNA function. Here, we show that fragile X mental retardation protein (FMRP) reads m6A to promote nuclear export of methylated mRNA targets during neural differentiation. Fmr1 knockout (KO) mice show delayed neural progenitor cell cycle progression and extended maintenance of proliferating neural progenitors into postnatal stages, phenocopying methyltransferase Mettl14 conditional KO (cKO) mice that have no m6A modification. RNA-seq and m6A-seq reveal that both Mettl14cKO and Fmr1KO lead to the nuclear retention of m6A-modified FMRP target mRNAs regulating neural differentiation, indicating that both m6A and FMRP are required for the nuclear export of methylated target mRNAs. FMRP preferentially binds m6A-modified RNAs to facilitate their nuclear export through CRM1. The nuclear retention defect can be mitigated by wild-type but not nuclear export-deficient FMRP, establishing a critical role for FMRP in mediating m6A-dependent mRNA nuclear export during neural differentiation.